AIDGenomics

We are a research and development-driven diagnostic company focused on the development of precision medicine-based diagnostic solutions primarily for oncology but also for hereditary rare diseases and infectious diseases.‍One of our primary goals is to enable patients around the world access to more accurate diagnostics and to ensure physicians have the diagnostic tools and data they need to make better therapy recommendations to patients.‍As a people and tech-led company, innovation is at the heart of what we do. Our mission is to improve patient care through individualized diagnostics and personalized medicine. That is why we are dedicated to delivering detailed, accurate, and comprehensive genomic insights that will help your doctor prescribe the most effective and efficient treatment. Much of our focus is dedicated to developing strong partnerships to deliver unique solutions that can improve survival and enhance the quality of life for those battling cancer. Established in 2018, AID Genomics is engaged in developing molecular diagnostics for personalized therapeutic approaches in oncology, genetics, and virology. In November 2020, AID Genomics built a highly automated laboratory in Jerusalem capable of running 70,000 COVID-19 PCR tests per day. Currently, the company is expanding its operations, services, and products in Israel and internationally, with a particular focus on the comprehensive sequencing of tissue and liquid biopsies. Snir co-founded AID Genomics with Kelvin and has served as CEO and director since 2018.